MAOB and Parkinson disease: The present study aimed to evaluate the impact of safinamide, a drug that, besides its activity as a reversible MAOB inhibitor, at a higher dose (100 mg), inhibits glutamate release at overactive synapses by blocking voltage-dependent calcium and sodium channels (Alborghetti and Nicoletti 2019; Jost 2022), on PD-related fatigue.